Retatrutide
$120
10 mg vial · lyophilised powder
A single peptide that acts on three hormone receptors at once: GIP, GLP‑1 and glucagon.
Retatrutide (LY3437943) was developed by Eli Lilly and is one of the most closely followed compounds in metabolic research. In published Phase 2 trials it produced large reductions in body weight in adults with obesity, and it is now in Phase 3 study. Researchers use it to examine appetite signalling, energy expenditure and blood‑sugar control.
- Class
- GIP / GLP‑1 / glucagon receptor agonist
- Vial
- 10 mg, lyophilised powder
- Storage
- −20 °C, dry and away from light